LDS/Medical Tests/ASXL1 Gene Mutation Analysis

ASXL1 Gene Mutation Analysis

The ASXL1 gene consists of 14 coding exons and located in the long (q) arm of chromosome 20 at position 11.21. It is a one of the Polycomb group of genes that encodes for Additional Sex Combs Like 1 (ASXL1) protein which is required for chromatin remodeling, and ultimately regulates the expression of certain gene activities. Most importantly, it regulates the expression of HOX genes which play a crucial role in fetal development before birth. The ASXL1 protein also regulates genes by mediating the process of DNA methylation in the promoter region of the genes. Mutations of ASXL1 gene are associated with Bohring-Opitz syndrome, myeloid leukemias, myeloproliferative disorders and mastocytosis.

Bohring-Opitz syndrome, also known as Oberklaid-Danks syndrome or C-like syndrome is an autosomal dominantly inherited condition characterized by distinctive facial features including exophthalmos, flat nasal bridge and cleft palate, abnormal head size and shape, and posture, growth failure with intellectual disability, seizures, and joint abnormalities. More than 20 mutations in the ASXL1 gene have been identified in this syndrome. Mutations may result in the production of nonfunctional protein or in a complete lack of ASXL1 protein leading to the neurological and physical characteristics of this rare disease.

Somatic mutations in the ASXL1 gene are associated with myeloid disorders. Mutations in exon 12 of ASXL1 gene have identified in 5% of de novo acute myeloid leukemia (AML) and almost 40% of chronic myelomonocytic leukemia. ASXL1 mutations also occur in about 15% of myelodysplastic syndromes (MDS) and 35% of primary myelofibrosis. The mutations associated with myeloid malignancies are believed to cause overexpression of ASXL1 protein (gain-of-function) which leads to poor regulation of gene activity and allows abnormal hematopoietic stem cells to grow uncontrollably. Genetic analysis of ASXL1 gene is particularly important in myeloid disorders as its presence appears to predict worse outcome across all myeloid neoplasms. The ASXL1 mutations are also commonly seen together with the mutation in SETBP1 in patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD).

  • Diagnostic confirmation of Bohring-Opitz Syndrome
  • Useful to evaluate prognostic outcomes in clonal myeloid disorders
Germline ASXL1 gene mutations are found. Nonsense or frameshift mutations are found in Bohring-Opitz Syndrome at a frequency of 50%. In AML patients, missense or frameshift mutations occur at a frequency of 10 % to 15%.

Negative for mutations analyzed (No mutation or pathogenic variant detected)

Next-Generation Sequencing (NGS) of all coding exons of the ASX1 gene, PCR and Bi-directional targeted sequence analysis.

Whole Blood collected (5ml) in purple top EDTA tube (preferred).

Bone marrow (2 -5ml) in EDTA tube.

FFPE tissue in paraffin block.

Stability

  • Room: 2-3 days
  • Refrigeration: 7 days
Sequencing of ANKRD26, ASXL1, BCOR, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KDM6A, KIT, KRAS, MPL, NPM1, NRAS, PHF6, PTPN11, RAD21, RUNX1, SETBP1, SH2B3, SF3B1, SRP72, SMC3, SRSF2, STAG2, TERT, TET2, TP53, U2AF1, WT1, and ZRSR2 genes are useful in diagnostic and prognostic evaluations of myeloid malignancies.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login